Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.
Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...
Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...
Daily Maverick on MSN2d
New chronic kidney disease treatments show promise, but are expensive and inaccessibleWhile the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...
Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...
Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback